TABLE 3

One-year measures of insulin secretion and sensitivity according to KCNJ11 E23K genotypes by treatment arm in the DPP

E/EE/KK/KP value*
Ins index [(μU/ml)/(mg/dl)]
    n1,6581,445364
    Placebo1.26 (1.18–1.35)1.15 (1.06–1.25)1.20 (1.02–1.39)0.24
    Metformin1.30 (1.21–1.39)1.09 (1.00–1.18)1.16 (0.95–1.36)0.005
    Lifestyle1.17 (1.08–1.26)1.26 (1.17–1.35)1.09 (0.91–1.27)0.18
    Troglitazone1.18 (1.02–1.34)1.26 (1.10–1.41)1.20 (0.87–1.53)0.78
ISI [(μU/ml) × (mmol/l)]−1
    n1,6881,474374
    Placebo0.184 (0.175–0.194)0.192 (0.181–0.202)0.213 (0.193–0.232)0.04
    Metformin0.235 (0.223–0.247)0.241 (0.229–0.254)0.194 (0.167–0.221)0.007
    Lifestyle0.265 (0.250–0.281)0.279 (0.263–0.295)0.271 (0.240–0.302)0.47
    Troglitazone0.274 (0.246–0.302)0.275 (0.248–0.302)0.256 (0.199–0.313)0.83
Fasting insulin (μU/ml)
    n1,6881,474374
    Placebo28 (26–29)28 (26–29)26 (23–29)0.53
    Metformin24 (23–25)24 (22–25)27 (24–29)0.04
    Lifestyle22 (21–23)21 (20–23)20 (18–23)0.61
    Troglitazone21 (19–22)21 (20–23)21 (17–24)0.90
  • Data are least-squares means (95% CI), adjusted for baseline values.

  • *

    * Nominal two-sided P values for the effect of E23K genotype are displayed; to correct for the number of hypotheses tested, a Bonferroni correction factor of ×5 can be applied (see text for details). Ins, insulinogenic; ISI, insulin sensitivity index.